Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: In vitro pharmacodynamic simulation

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 12, 1996, Pages 2904-2906

  Balcabao, I P ^a   Aguilar, L ^b   Martin M ^a   Garcia Y ^a   Dal RE R ^b   Prieto, J ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFOTAXIME;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

EID: 0029805020     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.12.2904     Document Type: Article

References (15)

1. Amsterdam, D. 1990. Assessing cidal activity of antimicrobial agents: problems and pitfalls. Antimicrob. Newsl. 7:49-56.
2. Amsterdam, D. 1992. The MIC: myth and reality. Antimicrob. Newsl. 8:9-16.
3. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:77-83.
4. Eagle, H. 1948. Speculations as to the therapeutic significance of the penicillin blood level. Ann. Intern. Med. 28:260-268.
5. Fraschini, F., F. Scaglione, M. Falchi, S. Dugnani, M. Mezzetti, F. Cicchetti, G. Alfano, and G. P. Pintucci. 1990. Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J. Chemother. 2:171-177.
6. Friedland, I. R., and H. McCraken. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.
7. Gerberding, J. L., and M. A. Sande. 1986. Limitations of animal models in predicting beta-lactam efficacy for endocarditis and meningitis. Rev. Infect. Dis. 8(Suppl. 3):315-318.
8. Lorian, V., and C. G. Gemmell. 1991. Effect of low antibiotic concentrations on bacteria: effects on ultrastructure, virulence, and susceptibility to immunodefenses, p. 493-555. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore.
9. Martín, M., L. Aguilar, I. P. Balcabao, M. L. Gómez-Lus, R. Dal-Ré, and J. Prieto. In-vitro pharmacodynamic simulation of clavulanic acid concentrations on Staphylococcus aureus and Haemophilus influenzae β-lactamase activity. J. Antimicrob. Chemother., in press.
10. Mattie, H. 1981. Kinetics of antimicrobial action. Rev. Infect. Dis. 3:19-27.
11. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
12. National Committee for Clinical Laboratory Standards. 1994. Perfomance standards for antimicrobial susceptibility testing, 5th international supplement. M-100-S5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. Pallarés, R., J. Liñares, M. Vadillo, C. Cabellos, F. Manresa, F. Viladrich, R. Martín, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
14. Soriano, F., C. Ponte, E. Nieto, and A. Parra. 1996. Correlation of "in vitro" activity and pharmacokinetic parameters with "in vivo" effect of amoxicillin, co-amoxiclav and cefotaxime in an experimental pneumonia with Streptococcus pneumoniae in mice. J. Antimicrob. Chemother. 38:227-236.
15. Wise, R., S. Baker, and R. Livingston. 1980. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels. Antimicrob. Agents Chemother. 18:369-371.